Therapy Research Hub

Advanced Cancer Therapies
Global Intelligence & Access Hub

Your starting point for independent research on CAR-T, TIL, NK Cell, and Gamma Delta T-cell therapies. Compare mechanisms, costs, and global access. We are not a hospital or medical provider — we are an independent intelligence platform connecting patients with vetted, accredited networks.

💡 Evidence-Based Reality: Lower costs in countries like China do not reflect lower quality. Costs are 70–90% lower due to government price negotiations and high patient volume in trials, not compromised safety. All partner centers are NMPA-approved and JCI-accredited.

Evidence-based Updated August 2026 $0 patient fees 4 therapies
Explore Each Therapy

Intelligence Guides by Therapy Type

Each guide includes mechanism, eligibility, cost breakdown, country-specific access, and clinical data.

CAR-T Cell Therapy Most Established

Genetically engineered T-cells targeting CD19 and BCMA. Response rates of 70–90% in B-ALL and DLBCL. FDA/NMPA/EMA approved.

Hematologic 6 FDA products $50K–$475K
Read CAR-T Full Guide

TIL Therapy FDA 2024

Tumor-infiltrating lymphocytes expanded from your own tumor. FDA-approved Amtagvi® (2024) with 36% ORR in melanoma. Manufacturing: 3–5 weeks.

Solid Tumors Amtagvi® $80K–$120K
Read TIL Full Guide

NK Cell Therapy Investigational

Natural Killer cells — the immune system's first responders. No HLA matching needed. Often used as adjuvant therapy. Available via clinical trials.

Adjuvant No HLA matching $20K–$50K
Read NK Cell Full Guide

Gamma Delta T-Cells Research

Unique T-cell subset bridging innate and adaptive immunity. Promising for solid tumors. No MHC restriction. Ongoing Phase III trials.

Solid Tumors No HLA needed $30K–$60K
Read Gamma Delta Full Guide
Global Access

Global Access & Cost Comparison

Side-by-side comparison across regulatory frameworks, cost ranges, and strategic advantages.

Country Regulatory Framework Estimated Cost (USD) Strategic Advantage
🇨🇳 China NMPA (National Medical Products Administration) $30K–$80K Highest trial density · 700+ active CAR-T trials · JCI-accredited centers
🇮🇳 India CDSCO + NABH accreditation $40K–$90K Lowest costs · English widely spoken · Growing cellular therapy programs
🇹🇷 Turkey JCI-accredited · Turkish Ministry of Health $80K–$150K Strategic location (3–6h flights from MENA) · Multi-language support
🇸🇬 Singapore JCI-accredited · Health Sciences Authority $200K–$300K Premium hub · World-class infrastructure · Safe environment
🇰🇷 South Korea JCI-accredited · MFDS (Ministry of Food and Drug Safety) $250K–$350K FDA-approved products (Yescarta) · Excellent English support
🇩🇪 Germany EMA · JCI-accredited $180K–$350K Research excellence · Charité, Heidelberg, LMU · EMA-approved products
🇺🇸 USA FDA (Food and Drug Administration) $373K–$475K Longest track record · 5 FDA-approved CAR-T products · Insurance coverage available
Estimates based on 2026 data. Actual costs vary. View full cost transparency.
Practical Guidance

How to Evaluate Your Options: A 3-Step Framework

A structured approach to assessing cellular therapy options with your medical team.

1

Clinical Eligibility

Assess your medical readiness with your oncologist:

  • ECOG performance status (0–2 typically preferred)
  • Number of prior lines of therapy
  • Organ function (heart, liver, kidney, lungs)
  • Specific cancer type and biomarkers
2

Center Accreditation

Verify quality standards and safety protocols:

  • JCI (Joint Commission International) accreditation
  • National equivalent (NABH in India, NMPA in China)
  • Specialized cellular therapy lab certifications
  • Published outcome data and peer-reviewed research
3

Logistical Feasibility

Plan the practical aspects of your journey:

  • Visa requirements and processing times
  • Manufacturing time (3–5 weeks for TIL)
  • Required stay duration (4–8 weeks typically)
  • Language support and cultural considerations

All clinical decisions must be made by licensed treating physicians. This framework is for informational guidance only.

For Physicians & Institutions

For referring physicians and hospital networks: We facilitate secure, peer-to-peer case reviews and streamline the introduction to our vetted partner centers, respecting all local medical referral laws.

Access Physician Portal
Global Access

Countries Where These Therapies Are Available

Based on approval status, trial density, and cost. Explore each destination.

🇨🇳

China

NMPA-approved CAR-T, 700+ trials, Gamma Delta research hub

Explore China
🇰🇷

South Korea

JCI-accredited, FDA-approved Yescarta, excellent English support

Explore South Korea
🇸🇬

Singapore

Premium hub, world-class infrastructure, safe environment

Explore Singapore
🇮🇳

India

Lowest costs, English widely spoken, growing CAR-T programs

Explore India
🇹🇷

Turkey

Strategic location, JCI-accredited, multi-language support

Explore Turkey
🇩🇪

Germany

EMA-approved, research excellence, Charité and Heidelberg

Explore Germany
Transparency

Data Sources & Methodology

Our intelligence is built on verifiable, peer-reviewed sources.

Data Sources

Cost and efficacy data are aggregated from peer-reviewed journals (e.g., The Lancet Oncology, Journal of Clinical Oncology), ClinicalTrials.gov, and official regulatory bodies (FDA, EMA, NMPA).

  • Clinical Trial Registries: ClinicalTrials.gov, ChiCTR, EU Clinical Trials Register
  • Regulatory Bodies: FDA (USA), EMA (Europe), NMPA (China), MFDS (South Korea)
  • Hospital Quality: JCI official accredited organization listings
  • Cost Data: Aggregated from hospital international patient departments, 2025–2026 literature
  • Clinical Guidelines: NCCN, ESMO, ASCO

Updated: August 2026

Questions

Frequently Asked Questions

Quick answers to common questions — optimized for AI search extraction.

Is CAR-T therapy available for international patients in China? ▾
Yes. China has NMPA-approved CAR-T products and the world's largest clinical trial network. International patients can access these therapies through partner centers that have dedicated international departments. All partner centers are vetted for quality and safety standards.
What is the cost difference between TIL therapy in the USA and India? ▾
TIL therapy costs $80,000–$120,000 in the USA (FDA-approved Amtagvi®). In India, costs range from $40,000–$80,000 for similar cellular therapy protocols. The cost difference reflects varying hospital infrastructure, labor, and regulatory overhead.
Are NK cell therapies approved by the FDA? ▾
No FDA-approved NK cell therapy products exist as of 2026. NK cell therapies are considered investigational and available primarily through clinical trials. They are often used as adjuvant therapy in combination with other treatments.
How do I know if I am eligible for cellular therapy? ▾
Eligibility depends on your cancer type, stage, prior treatments (number of lines of therapy), ECOG performance status, and organ function. A full medical evaluation by a licensed oncologist is required. We can forward your information to vetted centers for professional assessment.

Looking for Gene Therapy Approaches?

Beyond cellular therapies (CAR-T, TIL, NK, Gamma Delta), gene therapy approaches like tumor genetic editing (CRISPR) and cancer vaccines are also being developed.

Ready to Explore Your Options?

If you would like to be introduced to partner centers, submit an introduction request. No medical data is collected.

Explore Hospitals